IL-31 (Interleukin-31) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 23 Aug 2026
  • Comments

Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Atopic Dermatitis and Pruritus Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for IL-31 axis drug discovery.

Component / Network Product Description Product Link
Antigen IL-31 Recombinant Protein
HEK293 expressed, >95% purity (SDS-PAGE/HPLC), Endotoxin <1EU/μg, Sequence Verified.		 View IL31 Products
Receptor Subunit A IL-31RA ECD-Fc Fusion Protein
Extracellular domain for SPR/BLI binding assays.		 View IL31RA Products
Receptor Subunit B OSMRβ ECD-Fc Fusion Protein
Essential co-receptor component.		 View OSMR Products
Gene Delivery IL-31 Lentivirus Premade Particles
Full-length ORF for stable cell lines.		 View IL31 Products
Benchmark Ab Anti-IL-31RA Antibody (Nemolizumab Class)
Recombinant positive control for receptor blocking assays.		 View IL31RA Products
Validator IL-31 siRNA Set
For knockdown verification and specificity controls.		 View IL31 Products
Related Pathway Targets IL-4 / IL-13 / IL-31RA / OSMR
Synergistic Th2 cytokines and receptors for combination therapy.		 View IL4 Products, View IL13 Products

Critical Assay Challenges & TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Heterodimeric Receptor Complex (IL-31RA/OSMRβ) Binding Both IL-31RA and OSMRβ ECD-Fc proteins available for co-immobilization SPR/BLI assays; Sequence Verified.
Cross-species Cyno/Mouse Toxicology Evaluation Human, Cyno, and Mouse IL-31 ortholog proteins expressed in HEK293 with matched glycosylation profiles.
IL-6 Family Off-target Screening Homology panel available (IL-6, IL-11, OSM, LIF) for specificity confirmation against related gp130-family cytokines.
JAK/STAT Signaling Inhibition Confirmation Lentivirus-compatible ORF for generation of stable IL-31RA/OSMR reporter cell lines (pSTAT3/STAT1 luciferase).
High-concentration Subcutaneous Formulation Stability Aggregation-resistant protein design; Endotoxin controlled (<1EU/μg) for sensitive cellular assays.
Lack of Positive/Negative Controls Clinical Benchmark Antibodies (biosimilars) and validated siRNA included.

Live IL-31 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The IL-31 therapeutic landscape represents a paradigm shift from broad immunosuppression to targeted anti-pruritic therapy. With Nemolizumab (anti-IL-31RA) securing approval in Japan (2024) for Atopic Dermatitis (AD) and Prurigo Nodularis (PN), and EU approval for PN (2024), the validation of the IL-31/IL-31RA axis is established. The US PDUFA date of March 2025 for PN indicates imminent market expansion. The race for IL-31 therapeutics is intensifying, with major players shifting focus from traditional symptom management to targeted monoclonal antibodies.

Next-generation R&D is pivoting toward combination strategies (IL-31 blockade plus IL-4/IL-13 inhibition) for severe AD, and bispecific modalities targeting dual Th2 pathways, including extended half-life formulations and bispecific approaches to simultaneously block multiple Th2 cytokines. As first-generation antibodies establish safety profiles, the competitive differentiator lies in dosing convenience (subcutaneous quarterly dosing) and efficacy in treatment-resistant pruritus populations.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Anti-IL-31RA mAb Galderma/Maruho (Nemolizumab), Menarini Atopic Dermatitis, Prurigo Nodularis Receptor binding blockade (Need IL-31RA-Fc + IL-31 protein); pSTAT3 inhibition assay
Anti-IL-31 mAb Early-stage biotech Chronic Pruritus, AD Cytokine capture ELISA; Cyno cross-reactivity (Need Cyno IL-31 antigen)
Bispecific (Th2-focused) Sanofi, Regeneron; Preclinical/Discovery Severe AD, Eczema, Psoriasis overlap Simultaneous IL-31 and IL-4/IL-13 binding assays; Bivalent affinity ranking
Small Molecule (JAKi) Pfizer, AbbVie; Discovery stage Chronic Pruritus, Topical application Downstream pathway assay (Need stable IL-31 for induction); Protein-protein interaction disruption

深度战略与市场分析 (IL-31)

全球研发格局

IL-31/IL-31RA 通路已成为特应性皮炎（AD）和结节性痒疹（PN）引起的顽固性瘙痒的核心治疗靶点。2024年，靶向IL-31RA的Nemolizumab（由Chugai研发，Galderma商业化）在日本获批用于AD和PN，随后欧盟批准PN适应症，美国PDUFA日期为2025年3月，预示市场快速扩张。目前全球管线以单克隆抗体为主（约80%份额），小分子JAK抑制剂通过阻断下游STAT通路也占据一定地位。直接靶向IL-31配体的策略也在早期研发中，旨在从源头阻断瘙痒信号。

前瞻性市场预测

未来3-5年内，单纯靶向IL-31或IL-31RA的单抗将面临激烈竞争。市场趋势将向双特异性抗体（如IL-4R/IL-13/IL-31双抗）发展，以实现“止痒”与“抗炎”双重功效。为提升患者依从性，长效化（Fc工程延长半衰期）及皮下注射高浓度制剂开发成为核心重点。差异化关键包括：亲和力（亚纳摩尔级KD<1nM）、给药途径（皮下注射的溶解度与低粘度）、安全性（避免IL-6家族脱靶）、以及跨物种交叉反应性（支持临床前毒理）。

筛选Assay策略

推荐的中和活性验证使用表达IL-31RA/OSMR的细胞系，检测STAT3磷酸化抑制。高通量亲和力测定（SPR/BLI）需覆盖人、食蟹猴、小鼠IL-31。脱靶筛查应包含IL-6家族成员。TarMart提供HEK293表达、>95%纯度、低内毒素（<1EU/μg）的IL-31重组蛋白，以及直系同源蛋白支持跨物种评估。同时提供IL-31RA ECD-Fc、OSMRβ ECD-Fc、对照抗体和siRNA，全面支持受体结合、通路抑制及特异性验证。

关联靶点推荐

为支持多靶点及双抗研发，强烈推荐以下产品：